Literature DB >> 11901002

Whole-brain N-acetylaspartate concentration: correlation with T2-weighted lesion volume and expanded disability status scale score in cases of relapsing-remitting multiple sclerosis.

Fabrice Bonneville1, David M Moriarty, Belinda S Y Li, James S Babb, Robert I Grossman, Oded Gonen.   

Abstract

BACKGROUND AND
PURPOSE: The T2-weighted MR imaging total lesion volume and Expanded Disability Status Scale (EDSS) score are two common measures of relapsing-remitting multiple sclerosis disability and pathologic abnormality. Because the whole-brain N-acetylaspartate concentration is considered to be a new marker of the disease burden, the purpose of this study was to evaluate the relationship among these three measures.
METHODS: The whole-brain N-acetylaspartate concentration and T2-weighted lesion volume were quantified by using MR imaging and proton MR spectroscopy in 49 patients with relapsing-remitting multiple sclerosis (36 female and 13 male patients; average age, 39 years; age range, 24-55 years; average EDSS score, 2; range of EDSS scores, 0-6). Correlations among whole-brain N-acetylaspartate concentrations, T2-weighted lesion volumes, and EDSS scores were obtained.
RESULTS: No correlation was found between whole-brain N-acetylaspartate levels and either T2-weighted lesion volumes or EDSS scores. A weak correlation was found between the EDSS scores and T2-weighted lesion volumes (P =.043, r(s) = 0.292).
CONCLUSION: Despite the lack of correlation between whole-brain N-acetylaspartate concentration and the clinical disability reflected in the EDSS score, only the former evaluates the global neuronal cell disease in the entire brain, including those lesions that are occult to conventional imaging techniques.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11901002      PMCID: PMC7975304     

Source DB:  PubMed          Journal:  AJNR Am J Neuroradiol        ISSN: 0195-6108            Impact factor:   3.825


  47 in total

1.  Interrater variability with the Expanded Disability Status Scale (EDSS) and Functional Systems (FS) in a multiple sclerosis clinical trial. The Canadian Cooperation MS Study Group.

Authors:  J H Noseworthy; M K Vandervoort; C J Wong; G C Ebers
Journal:  Neurology       Date:  1990-06       Impact factor: 9.910

2.  1H MRSI comparison of white matter and lesions in primary progressive and relapsing-remitting MS.

Authors:  J Suhy; W D Rooney; D E Goodkin; A A Capizzano; B J Soher; A A Maudsley; E Waubant; P B Andersson; M W Weiner
Journal:  Mult Scler       Date:  2000-06       Impact factor: 6.312

3.  Correlations between changes in disability and T2-weighted brain MRI activity in multiple sclerosis: a follow-up study.

Authors:  M Filippi; D W Paty; L Kappos; F Barkhof; D A Compston; A J Thompson; G J Zhao; C M Wiles; W I McDonald; D H Miller
Journal:  Neurology       Date:  1995-02       Impact factor: 9.910

Review 4.  Nuclear magnetic resonance spectroscopy studies of the brain.

Authors:  R A Kauppinen; S R Williams
Journal:  Prog Neurobiol       Date:  1994-09       Impact factor: 11.685

5.  Imaging of axonal damage in multiple sclerosis: spatial distribution of magnetic resonance imaging lesions.

Authors:  S Narayanan; L Fu; E Pioro; N De Stefano; D L Collins; G S Francis; J P Antel; P M Matthews; D L Arnold
Journal:  Ann Neurol       Date:  1997-03       Impact factor: 10.422

6.  Axonal dysfunction and disability in a relapse of multiple sclerosis: longitudinal study of a patient.

Authors:  N De Stefano; P M Matthews; S Narayanan; G S Francis; J P Antel; D L Arnold
Journal:  Neurology       Date:  1997-10       Impact factor: 9.910

7.  Immunocytochemical localization of N-acetyl-aspartate with monoclonal antibodies.

Authors:  M L Simmons; C G Frondoza; J T Coyle
Journal:  Neuroscience       Date:  1991       Impact factor: 3.590

8.  High resolution proton NMR spectroscopy of multiple sclerosis lesions.

Authors:  S E Davies; J Newcombe; S R Williams; W I McDonald; J B Clark
Journal:  J Neurochem       Date:  1995-02       Impact factor: 5.372

9.  Progressive cerebral atrophy in MS: a serial study using registered, volumetric MRI.

Authors:  N C Fox; R Jenkins; S M Leary; V L Stevenson; N A Losseff; W R Crum; R J Harvey; M N Rossor; D H Miller; A J Thompson
Journal:  Neurology       Date:  2000-02-22       Impact factor: 9.910

10.  Kurtzke scales revisited: the application of psychometric methods to clinical intuition.

Authors:  J Hobart; J Freeman; A Thompson
Journal:  Brain       Date:  2000-05       Impact factor: 13.501

View more
  10 in total

Review 1.  [Multiple sclerosis].

Authors:  I Q Grunwald; A L Kühn; M Backens; K Shariat; P Kostopoulos; P Papanagiotou
Journal:  Radiologe       Date:  2008-06       Impact factor: 0.635

Review 2.  MRI in multiple sclerosis: what's inside the toolbox?

Authors:  Mohit Neema; James Stankiewicz; Ashish Arora; Zachary D Guss; Rohit Bakshi
Journal:  Neurotherapeutics       Date:  2007-10       Impact factor: 7.620

Review 3.  MRI evidence for multiple sclerosis as a diffuse disease of the central nervous system.

Authors:  Massimo Filippi; Maria Assunta Rocca
Journal:  J Neurol       Date:  2005-11       Impact factor: 4.849

4.  Reduced NAA-levels in the NAWM of patients with MS is a feature of progression. A study with quantitative magnetic resonance spectroscopy at 3 Tesla.

Authors:  Fahmy Aboul-Enein; Martin Krssák; Romana Höftberger; Daniela Prayer; Wolfgang Kristoferitsch
Journal:  PLoS One       Date:  2010-07-20       Impact factor: 3.240

5.  Axonal injury detected by in vivo diffusion tensor imaging correlates with neurological disability in a mouse model of multiple sclerosis.

Authors:  Matthew D Budde; Joong Hee Kim; Hsiao-Fang Liang; John H Russell; Anne H Cross; Sheng-Kwei Song
Journal:  NMR Biomed       Date:  2008-07       Impact factor: 4.044

6.  Fully automated open-source lesion mapping of T2-FLAIR images with FSL correlates with clinical disability in MS.

Authors:  Nathan C Wetter; Elizabeth A Hubbard; Robert W Motl; Bradley P Sutton
Journal:  Brain Behav       Date:  2016-01-28       Impact factor: 2.708

Review 7.  Quantifying the Metabolic Signature of Multiple Sclerosis by in vivo Proton Magnetic Resonance Spectroscopy: Current Challenges and Future Outlook in the Translation From Proton Signal to Diagnostic Biomarker.

Authors:  Kelley M Swanberg; Karl Landheer; David Pitt; Christoph Juchem
Journal:  Front Neurol       Date:  2019-11-15       Impact factor: 4.003

Review 8.  The role of nonconventional magnetic resonance imaging techniques in demyelinating disorders.

Authors:  Francesca Bagnato; Joseph A Frank
Journal:  Curr Neurol Neurosci Rep       Date:  2003-05       Impact factor: 6.030

9.  Magnetic resonance spectroscopy of normal appearing white matter in early relapsing-remitting multiple sclerosis: correlations between disability and spectroscopy.

Authors:  Juan Luis Ruiz-Peña; Pilar Piñero; Guillermo Sellers; Joaquín Argente; Alfredo Casado; Jesus Foronda; Antonio Uclés; Guillermo Izquierdo
Journal:  BMC Neurol       Date:  2004-06-10       Impact factor: 2.474

10.  Extracellular N-Acetylaspartate in Human Traumatic Brain Injury.

Authors:  Richard J Shannon; Susan van der Heide; Eleanor L Carter; Ibrahim Jalloh; David K Menon; Peter J Hutchinson; Keri L H Carpenter
Journal:  J Neurotrauma       Date:  2015-08-14       Impact factor: 5.269

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.